Inhibitory effect of Mercurascan on lymphocytes.
Human lymphocytes treated in vitro with Mercurascan (MSC) have a reduced capacity to form E rosettes and to respond to phytohemagglutinin. MSC was also found to reduce the capacity of mouse lymphocytes to activate the regional lymph nodes of allogeneic recipients and release the lymph node-activating factor.